teduglutide

Teduglutide is a recombinant analog of human glucagon-like peptide-2 (GLP-2), developed for the treatment of short bowel syndrome (SBS) in patients who require parenteral nutritional support. It is a 33-amino acid peptide that differs from endogenous GLP-2 by a single amino acid substitution, making it more resistant to degradation and extending its half-life. Teduglutide acts as an agonist at the glucagon-like peptide 2 receptor, promoting mucosal growth, increasing intestinal and portal blood flow, inhibiting gastric acid secretion, and enhancing absorption of fluids and nutrients in the intestines. The drug was first approved in 2012 under the brand names Gattex (US) and Revestive (EU). It is administered via subcutaneous injection[1][3][4][5].

Brand names

GattexRevestive

Other names

Glucagon-Like Peptide 2 analogueGLP-2 analogueGLP2 analogueGLP 2 analogue